Literature DB >> 8056190

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment.

P Rossing1, E Hommel, U M Smidt, H H Parving.   

Abstract

Diabetic nephropathy is the main cause of increased mortality and morbidity in IDDM patients. The effect of antihypertensive treatment on the progression of the nephropathy is highly variable. The aim of this study was to evaluate putative predictors of the progression in diabetic nephropathy during long-term antihypertensive treatment. Eighteen hypertensive IDDM patients with diabetic nephropathy, who had not been treated previously, were followed during 3 years of treatment with captopril and frusemide or bendrofluazide. Glomerular filtration rate, arterial blood pressure, albuminuria and adjusted albuminuria were used as putative predictors of rate of decline in glomerular filtration. Fall rate in glomerular filtration rate was 4.6 (4.0) ml.min-1.year-1 (mean (SD)) during treatment. Relative change in albuminuria (ratio of first year of treatment/baseline) and albuminuria during first year of treatment were significantly correlated to fall rate in glomerular filtration rate during 3 years of treatment (r = 0.73, p < 0.001) and (r = 0.60, p < 0.01), respectively. Arterial blood pressure and glomerular filtration rate measured at baseline, during first year of treatment or relative changes in these variables did not correlate with fall rate in glomerular filtration rate during 3 years of treatment. Haemoglobin A1c, serum-cholesterol, protein intake and sodium excretion remained unchanged during treatment, and were not correlated with loss of kidney function. Reduction in albuminuria during captopril treatment predicts an attenuated rate of decline in glomerular filtration rate in early diabetic nephropathy (glomerular filtration rate > 70 ml.min-1.1.73 m-2). The finding suggests a clinical application in monitoring the efficacy of antihypertensive treatment in early diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056190     DOI: 10.1007/s001250050140

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  39 in total

1.  Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats.

Authors:  B L Kasiske; M P O'Donnell; M P Cleary; W F Keane
Journal:  Kidney Int       Date:  1988-03       Impact factor: 10.612

2.  Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1976-07       Impact factor: 1.713

3.  The modification of diet in renal disease study.

Authors:  S Klahr
Journal:  N Engl J Med       Date:  1989-03-30       Impact factor: 91.245

Review 4.  Reduction in proteinuria attenuates hyperlipidemia in the nephrotic syndrome.

Authors:  G A Kaysen; R W Davies
Journal:  J Am Soc Nephrol       Date:  1990-11       Impact factor: 10.121

5.  Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy.

Authors:  E Morelli; N Loon; T Meyer; W Peters; B D Myers
Journal:  Diabetes       Date:  1990-01       Impact factor: 9.461

6.  Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.

Authors:  J F Moorhead; M K Chan; M El-Nahas; Z Varghese
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

7.  Renal protective effect of enalapril in diabetic nephropathy.

Authors:  S Björck; H Mulec; S A Johnsen; G Nordén; M Aurell
Journal:  BMJ       Date:  1992-02-08

8.  A method for estimating nitrogen intake of patients with chronic renal failure.

Authors:  B J Maroni; T I Steinman; W E Mitch
Journal:  Kidney Int       Date:  1985-01       Impact factor: 10.612

9.  Hemodynamically mediated glomerular injury and the progressive nature of kidney disease.

Authors:  B M Brenner
Journal:  Kidney Int       Date:  1983-04       Impact factor: 10.612

10.  Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy.

Authors:  C E Mogensen
Journal:  Br Med J (Clin Res Ed)       Date:  1982-09-11
View more
  35 in total

Review 1.  Integrating albuminuria and GFR in the assessment of diabetic nephropathy.

Authors:  George Jerums; Sianna Panagiotopoulos; Erosha Premaratne; Richard J MacIsaac
Journal:  Nat Rev Nephrol       Date:  2009-07       Impact factor: 28.314

2.  Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-12-09       Impact factor: 10.122

3.  The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Hans-Henrik Parving; Peter Rossing; Hiddo Jan Lambers Heerspink
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

4.  Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?

Authors:  Peter Rossing
Journal:  Nat Rev Nephrol       Date:  2013-02-05       Impact factor: 28.314

5.  Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Ravi Nistala; Javad Habibi; Melvin R Hayden; Rebecca I Schneider; Megan S Johnson; Roger Tilmon; Nathan Rehmer; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-09

Review 6.  Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.

Authors:  Francesca Cagnoni; Christian Achiri Ngu Njwe; Augusto Zaninelli; Alessandra Rossi Ricci; Diletta Daffra; Antonio D'Ospina; Paola Preti; Maurizio Destro
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

7.  Role of remission clinics in the longitudinal treatment of CKD.

Authors:  Piero Ruggenenti; Elena Perticucci; Paolo Cravedi; Vincenzo Gambara; Marco Costantini; Sanjib Kumar Sharma; Annalisa Perna; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

8.  Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Authors:  Stine E Nielsen; Takeshi Sugaya; Lise Tarnow; Maria Lajer; Katrine J Schjoedt; Anne Sofie Astrup; Tsuneharu Baba; Hans-Henrik Parving; Peter Rossing
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 19.112

9.  Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.

Authors:  Frederik Persson; Peter Rossing; Henrik Reinhard; Tina Juhl; Coen D A Stehouwer; Casper Schalkwijk; A H Jan Danser; Frans Boomsma; Erik Frandsen; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2009-07-08       Impact factor: 19.112

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.